NCT00430508 - Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension | Biotech Hunter

Enrollment

972

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

May 31, 2008

Conditions

Essential Hypertension

Interventions

DRUG

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week

DRUG

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks

DRUG

olmesartan medoxomil/hydrochlorothiazide tablets

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks

DRUG

olmesartan medoxomil/hydrochlorothiazide tablets

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks

Trial Locations (55)

Unknown

Pleven

Sofia

Beroun

Brno

Chrudim

Hradec Králové

Jindřichův Hradec

Kutná Hora

Ostrava

Pardubice

Pilsen

Prague

Příbram

Řevnice

Sokolov

Trutnov

Langres

Paris

Pessac

Berlin

Bochum

Dietzenbach

Franfurt

Friedberg

Ingelheim

Karlsbad

Leipzig

Offenbach

Siegen

Stuhr-Brinkum

Elblag

Gdansk

Inowrocław

Katowice

Krakow

Linia

Lodz

Oława

Poznan

Warsaw

Wroclaw

Zamość

Girona

Granada

Madrid

Oviedo

Dnipro

Donetsk

Kharkiv

Kiev

Lviv

Odesa

Uzhhorod

Vinnytsia

Zaporizhzhya